CLINICAL TRIALS IN
TARGETED THERAPY
Trials are how the next generation of targeted therapy reaches patients. Some of today's most effective treatments -- osimertinib, lorlatinib, T-DXd -- were accessed through trial enrollment years before commercial approval.
analyticsAt a Glance
- check_circleTargeted therapy trials match patients to drugs based on specific mutations or gene alterations
- check_circleKRAS G12C, BRAF, RET, and HER3 are among the most active current trial targets
- check_circleBiomarker testing via NGS is required before applying to most targeted therapy trials
- check_circleTrials in China and India may be accessible to international patients through CancerFax
Types of Targeted Therapy Trials
Different trial designs serve different clinical purposes. Understanding them helps patients identify which type of trial applies to their situation.
Basket Trials
Enrol patients based on a specific mutation across multiple cancer types rather than by tumour location. If you have NTRK fusion, RET fusion, or another tumour-agnostic mutation, you may qualify regardless of where the cancer originated.
Umbrella Trials
Run across multiple biomarker subgroups within a single cancer type. Patients are matched to a specific sub-protocol based on molecular profile. Common in lung cancer. Highly efficient for molecularly heterogeneous diseases.
Phase I Trials
First-in-human studies testing new targeted agents. Typically for patients who have exhausted standard options. May offer access to genuinely novel mechanisms well before any commercial approval.
Expanded Access
For patients who do not qualify for trials but for whom no approved option remains. The treating oncologist typically initiates this request with the manufacturer. Availability varies considerably by company and country.
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Find Clinical Trials for Your Targeted Therapy Mutation?
CancerFax identifies currently enrolling targeted therapy trials matched to your specific mutation type and prior treatment history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.